{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:14:24Z","timestamp":1790378064598,"version":"4.1.0"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.lfs.2019.02.029","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T20:58:01Z","timestamp":1550782681000},"page":"362-376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":159,"special_numbering":"C","title":["Glaucoma: Current treatment and impact of advanced drug delivery systems"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1620-0547","authenticated-orcid":false,"given":"Khushwant S.","family":"Yadav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Rajpurohit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushmita","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2019.02.029_bb0005","first-page":"1","article-title":"Background of ocular drug delivery","author":"Bamiro","year":"2016","journal-title":"Ocul. Drug Deliv. Adv. Challenges Appl."},{"key":"10.1016\/j.lfs.2019.02.029_bb0010","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/sj.eye.6702498","article-title":"Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion","volume":"22","author":"Noma","year":"2008","journal-title":"Eye."},{"key":"10.1016\/j.lfs.2019.02.029_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172481","article-title":"Characterization of the human aqueous humour proteome: a comparison of the genders","volume":"12","author":"Perumal","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2019.02.029_bb0020","unstructured":"G. Baerveldt, pharmacia and Upjohn Co US, Method and apparatus for inserting a glaucoma implant in an anterior and posterior segment of the eye, US Patent (2000) Patent 6050970."},{"key":"10.1016\/j.lfs.2019.02.029_bb0025","series-title":"Handbook of Emergency Ophthalmology","first-page":"1","article-title":"Anatomy of the eye","author":"Ng","year":"2018"},{"key":"10.1016\/j.lfs.2019.02.029_bb0030","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/adhm.201400504","article-title":"Contact lens sensors in ocular diagnostics","volume":"4","author":"Farandos","year":"2015","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.lfs.2019.02.029_bb0035","first-page":"1","article-title":"The effects of cigarette smoking on intraocular pressure and arterial blood pressure of normotensive young Nigerian male adults","volume":"22","author":"Timothy","year":"2007","journal-title":"Niger. J. Physiol. Sci."},{"key":"10.1016\/j.lfs.2019.02.029_bb0040","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.sna.2013.08.029","article-title":"Capacitive contact lens sensor for continuous non-invasive intraocular pressure monitoring","volume":"203","author":"Chen","year":"2013","journal-title":"Sensors Actuators A Phys."},{"key":"10.1016\/j.lfs.2019.02.029_bb0045","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.lfs.2019.02.029_bb0050","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjo.2005.081224","article-title":"The number of people with glaucoma worldwide in 2010 and 2020","volume":"90","author":"Quigley","year":"2006","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.lfs.2019.02.029_bb0055","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.1093\/hmg\/ddr382","article-title":"Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma in Caucasians from the USA","volume":"20","author":"Wiggs","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.lfs.2019.02.029_bb0060","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0002-9394(85)90001-7","article-title":"Race and primary open-angle glaucoma","volume":"99","author":"Martin","year":"1985","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.lfs.2019.02.029_bb0065","first-page":"532","article-title":"Prevalence of open-angle glaucoma among adults in the United States","author":"Friedman","year":"2004","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.lfs.2019.02.029_bb0070","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0161-6420(96)30573-3","article-title":"Glaucoma care and conformance with preferred practice patterns: examination of the private, community-based ophthalmologist","volume":"103","author":"Hertzog","year":"1996","journal-title":"Ophthalmology."},{"key":"10.1016\/j.lfs.2019.02.029_bb0075","doi-asserted-by":"crossref","first-page":"e794","DOI":"10.1111\/aos.13365","article-title":"The role of hypertension in retinal blood flow alterations in open-angle glaucoma patients","volume":"95","author":"Ciulla","year":"2017","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.lfs.2019.02.029_bb0080","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(04)17179-1","article-title":"Primary open-angle glaucoma: pathophysiology and treatment","volume":"364","author":"Kountouras","year":"2004","journal-title":"Lancet."},{"key":"10.1016\/j.lfs.2019.02.029_bb0085","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0161-6420(99)90500-6","article-title":"Management of uveitic glaucoma with Ahmed glaucoma valve implantation","volume":"106","author":"Da Mata","year":"1999","journal-title":"Ophthalmology."},{"key":"10.1016\/j.lfs.2019.02.029_bb0090","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/ajhp\/62.7.691","article-title":"Glaucoma and its treatment: a review","volume":"62","author":"Lee","year":"2005","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.lfs.2019.02.029_bb0095","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/oxfordjournals.aje.a113626","article-title":"The epidemiology of open-angle glaucoma: a review","volume":"118","author":"Leske","year":"1983","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.lfs.2019.02.029_bb0100","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.survophthal.2008.08.006","article-title":"Risk factors for glaucoma onset and progression","volume":"53","author":"Coleman","year":"2008","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.lfs.2019.02.029_bb0105","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.addr.2005.09.005","article-title":"Intraocular sustained drug delivery using implantable polymeric devices","volume":"57","author":"Yasukawa","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.lfs.2019.02.029_bb0110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0169-409X(95)00013-W","article-title":"Bioadhesive and phase-change polymers for ocular drug delivery","volume":"16","author":"Robinson","year":"1995","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.lfs.2019.02.029_bb0115","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1517\/17425247.5.5.567","article-title":"Ocular novel drug delivery: impacts of membranes and barriers","volume":"5","author":"Barar","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.lfs.2019.02.029_bb0120","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1081\/DDC-100102312","article-title":"Development of model aqueous ophthalmic solution of indomethacin","volume":"26","author":"Dimitrova","year":"2000","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.lfs.2019.02.029_bb0125","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijpharm.2015.01.032","article-title":"Liposome incorporated ion sensitive in-situ gels for opthalmic delivery of timolol maleate","volume":"480","author":"Yu","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.lfs.2019.02.029_bb0130","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4103\/0250-474X.32105","article-title":"Long acting ophthalmic formulation of indomethacin: evaluation of alginate gel systems","volume":"69","author":"Bharathi","year":"2007","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.lfs.2019.02.029_bb0135","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/IJG.0000000000000729","article-title":"Can adapted motivational interviewing improve uptake of surgical or laser treatment for glaucoma in Nigeria: randomized controlled trial","volume":"26","author":"Abdull","year":"2017","journal-title":"J. Glaucoma"},{"key":"10.1016\/j.lfs.2019.02.029_bb0140","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/eye.2013.267","article-title":"Selective laser trabeculoplasty (SLT) vs other treatment modalities for glaucoma: systematic review","volume":"28","author":"McAlinden","year":"2014","journal-title":"Eye."},{"key":"10.1016\/j.lfs.2019.02.029_bb0145","series-title":"Ophthalmology Secrets in Color E-Book","author":"Gault","year":"2015"},{"key":"10.1016\/j.lfs.2019.02.029_bb0150","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jconrel.2015.01.023","article-title":"Sustained drug release by contact lenses for glaucoma treatment\u2014a review","volume":"202","author":"Carvalho","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2019.02.029_bb0155","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/eye.2011.309","article-title":"Current concepts on primary open-angle glaucoma genetics: a contribution to disease pathophysiology and future treatment","volume":"26","author":"Gemenetzi","year":"2012","journal-title":"Eye."},{"key":"10.1016\/j.lfs.2019.02.029_bb0160","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1167\/iovs.02-0666","article-title":"Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes","volume":"44","author":"Liu","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.lfs.2019.02.029_bb0165","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1517\/13543784.10.4.679","article-title":"Therapeutic potential of prostaglandin analogues in glaucoma","volume":"10","author":"Lind\u00e9n","year":"2001","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.lfs.2019.02.029_bb0170","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/eye.2011.82","article-title":"Novel drug delivery systems for glaucoma","volume":"25","author":"Lavik","year":"2011","journal-title":"Eye."},{"key":"10.1016\/j.lfs.2019.02.029_bb0175","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4103\/0253-7613.44151","article-title":"Recent advances in pharmacotherapy of glaucoma","volume":"40","author":"Gupta","year":"2008","journal-title":"Indian J. Pharm."},{"key":"10.1016\/j.lfs.2019.02.029_bb0180","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0161-6420(79)35535-X","article-title":"Timolol: its effectiveness in different types of glaucoma","volume":"86","author":"Wilson","year":"1979","journal-title":"Ophthalmology."},{"key":"10.1016\/j.lfs.2019.02.029_bb0185","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0002-9394(14)74987-6","article-title":"Hematologic reactions to carbonic anhydrase inhibitors","volume":"100","author":"Fraunfelder","year":"1985","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.lfs.2019.02.029_bb0190","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/S0161-6420(98)91047-8","article-title":"A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide 1","volume":"105","author":"Clineschmidt","year":"1998","journal-title":"Ophthalmology."},{"key":"10.1016\/j.lfs.2019.02.029_bb0195","first-page":"115","article-title":"Joint meeting with National Society for Prevention of Blindness: the mechanism of action of adrenergic drugs in glaucoma","volume":"5","author":"Sears","year":"1996","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.lfs.2019.02.029_bb0200","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"Weinreb","year":"2014","journal-title":"Jama."},{"key":"10.1016\/j.lfs.2019.02.029_bb0205","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/archopht.1987.01060090063028","article-title":"The safety and efficacy of topical 1% ALO 2145 (p-aminoclonidine hydrochloride) in normal volunteers","volume":"105","author":"Abrams","year":"1987","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.lfs.2019.02.029_bb0210","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJM199810293391808","article-title":"Medical management of glaucoma","volume":"339","author":"Alward","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2019.02.029_bb0215","unstructured":"R. Ritch, E.E. Klein, Method for the treatment of glaucoma, U.S. Patent, 5092837 (1992)."},{"key":"10.1016\/j.lfs.2019.02.029_bb0220","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/aos.12784","article-title":"Primary angle-closure glaucoma: an update","volume":"94","author":"Wright","year":"2016","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.lfs.2019.02.029_bb0225","first-page":"1198","article-title":"Reduction of intraocular pressure in glaucomatous dogs by a new cholinergic drug","volume":"19","author":"Chiou","year":"1980","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.lfs.2019.02.029_bb0230","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1016\/S0039-6257(02)00309-0","article-title":"Latanoprost and cholinergic agonists in combination","volume":"47","author":"Toris","year":"2002","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.lfs.2019.02.029_bb0235","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.msec.2014.10.043","article-title":"Applications of nanoparticles in treatment and diagnosis of leukemia","volume":"47","author":"Soni","year":"2015","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.lfs.2019.02.029_bb0240","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jsps.2014.04.001","article-title":"Nanogels as potential nanomedicine carrier for treatment of cancer: a mini review of the state of the art","volume":"24","author":"Soni","year":"2016","journal-title":"Saudi. Pharm. J."},{"key":"10.1016\/j.lfs.2019.02.029_bb0245","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.drudis.2013.10.001","article-title":"In-situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations","volume":"19","author":"Almeida","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.lfs.2019.02.029_bb0250","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jconrel.2009.02.013","article-title":"Thixotropic property in pharmaceutical formulations","volume":"136","author":"Lee","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2019.02.029_bb0255","first-page":"1","article-title":"Development and characterization of in-situ gel for ophthalmic formulation containing ciprofloxacin hydrochloride","volume":"6","author":"Makwana","year":"2016","journal-title":"Res. Pharm. Sci."},{"key":"10.1016\/j.lfs.2019.02.029_bb0260","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/jps.2600840315","article-title":"Modification of in-situ gelling behavior of carbopol solutions by hydroxypropyl methylcellulose","volume":"84","author":"Kumar","year":"1995","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.lfs.2019.02.029_bb0265","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3797\/scipharm.1001-06","article-title":"Carbopol\/chitosan based pH triggered in-situ gelling system for ocular delivery of timolol maleate","volume":"78","author":"Gupta","year":"2010","journal-title":"Sci. Pharm."},{"key":"10.1016\/j.lfs.2019.02.029_bb0270","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/10837450.2017.1328693","article-title":"Increasing efficacy and reducing systemic absorption of brimonidine tartrate ophthalmic gels in rabbits","volume":"23","author":"Pang","year":"2018","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.lfs.2019.02.029_bb0275","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/21691401.2018.1559176","article-title":"Polymers, responsiveness and cancer therapy","volume":"47","author":"Pethe","year":"2019","journal-title":"Artif Cells Nanomed Biotechnol."},{"key":"10.1016\/j.lfs.2019.02.029_bb0280","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1080\/10717544.2016.1223225","article-title":"Development of loteprednoletabonate-loaded cationic nanoemulsifiedin-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability","volume":"23","author":"Patel","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.lfs.2019.02.029_bb0285","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11095-017-2110-x","article-title":"Nimodipine ophthalmic formulations for management of glaucoma","volume":"34","author":"Maria","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.lfs.2019.02.029_bb0290","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ejpb.2010.02.011","article-title":"A poloxamer\/chitosan in-situ forming gel with prolonged retention time for ocular delivery","volume":"75","author":"Gratieri","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.lfs.2019.02.029_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/21691401.2015.1012260","article-title":"In-situ nasal gel drug delivery: a novel approach for brain targeting through the mucosal membrane","volume":"44","author":"Kaur","year":"2015","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.lfs.2019.02.029_bb0300","first-page":"1","article-title":"Research progress in in-situ gelling ophthalmic drug delivery system","volume":"14","author":"Wu","year":"2018","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.lfs.2019.02.029_bb0305","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.3109\/10717544.2014.987333","article-title":"Preparation and evaluation of nanoparticles loaded ophthalmic in-situ gel","volume":"23","author":"Kesarla","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.lfs.2019.02.029_bb0310","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2147\/DDDT.S153405","article-title":"A novel ocular delivery of brinzolamide based on gellan gum: in vitro and in vivo evaluation","volume":"12","author":"Sun","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.lfs.2019.02.029_bb0315","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3109\/03639045.2012.736515","article-title":"Recent advances in ocular drug delivery","volume":"39","author":"Achouri","year":"2013","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.lfs.2019.02.029_bb0320","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/10717540701606426","article-title":"Sustained ocular drug delivery from a temperature and pH triggered novel in-situ gel system","volume":"14","author":"Gupta","year":"2007","journal-title":"Drug Deliv."},{"key":"10.1016\/j.lfs.2019.02.029_bb0325","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3109\/10611860903508788","article-title":"Ion- and pH-activated novel in-situ gel system for sustained ocular drug delivery","volume":"18","author":"Gupta","year":"2010","journal-title":"J. Drug Target."},{"key":"10.1016\/j.lfs.2019.02.029_bb0330","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-2836(65)80093-6","article-title":"Diffusion of univalent ions across the lamellae of swollen phospholipids","volume":"13","author":"Bangham","year":"1965","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.lfs.2019.02.029_bb0335","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3109\/10717544.2014.943336","article-title":"Liposomes in topical ophthalmic drug delivery: an update","volume":"23","author":"Agarwal","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.lfs.2019.02.029_bb0340","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00003088-199121030-00001","article-title":"Liposomal drug delivery, advantages and limitations from a clinical pharmacokinetic and therapeutic perspective","volume":"21","author":"Fielding","year":"1991","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.lfs.2019.02.029_bb0345","article-title":"Development and in vitro\/in vivo evaluation of liposomal gels for the sustained ocular delivery of latanoprost","volume":"6","author":"Fathalla","year":"2015","journal-title":"J. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.lfs.2019.02.029_bb0350","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/08982104.2016.1275679","article-title":"Entrapment efficiency of pyridoxine hydrochloride in unilamellar liposomes: experimental versus model-generated data","volume":"28","author":"Abd-El-Azim","year":"2018","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.lfs.2019.02.029_bb0355","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2147\/IJN.S122747","article-title":"A novel ion-exchange carrier based upon liposome-encapsulated montmorillonite for ophthalmic delivery of betaxolol hydrochloride","volume":"12","author":"Huang","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.lfs.2019.02.029_bb0360","first-page":"123","article-title":"Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye","volume":"7","author":"Natarajan","year":"2012","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.lfs.2019.02.029_bb0365","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ijpharm.2018.07.012","article-title":"Treatment merits of latanoprost\/thymoquinone\u2013encapsulated liposome for glaucomatus rabbits","volume":"548","author":"Fahmy","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.lfs.2019.02.029_bb0370","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/03639045.2017.1386196","article-title":"Dorzolamidenanoliposome as a long action ophthalmic delivery system in open angle glaucoma and ocular hypertension patients","volume":"44","author":"Kouchak","year":"2018","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.lfs.2019.02.029_bb0375","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/10717544.2013.838077","article-title":"Recent advances in non-ionic surfactant vesicles (niosomes): self-assembly, fabrication, characterization, drug delivery applications and limitations","volume":"21","author":"Abdelkader","year":"2014","journal-title":"Drug Deliv."},{"key":"10.1016\/j.lfs.2019.02.029_bb0380","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cis.2013.11.018","article-title":"Niosomes from 80s to present: the state of the art","volume":"205","author":"Marianecci","year":"2014","journal-title":"Adv. Colloid Interf. Sci."},{"key":"10.1016\/j.lfs.2019.02.029_bb0385","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.2042-7158.1985.tb05051.x","article-title":"The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice","volume":"37","author":"Azmin","year":"1985","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.lfs.2019.02.029_bb0390","first-page":"413","article-title":"Dorzolamide loaded niosomal vesicles: comparison of passive and remote loading methods","volume":"16","author":"Dehaghi","year":"2017","journal-title":"Iran J. Pharm. Res."},{"key":"10.1016\/j.lfs.2019.02.029_bb0395","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3109\/10837450.2013.819014","article-title":"High encapsulation efficiency of poloxamer-based injectable thermoresponsive hydrogels of etoposide","volume":"19","author":"Soni","year":"2014","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.lfs.2019.02.029_bb0400","series-title":"Modeling, Methodologies and Tools for Molecular and Nano-scale Communications","first-page":"503","article-title":"Communication of drug loaded nanogels with cancer cell receptors for targeted delivery","author":"Soni","year":"2017"},{"key":"10.1016\/j.lfs.2019.02.029_bb0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0169-409X(93)90025-Y","article-title":"Preparation, structure and diffusional behavior of hydrogels in controlled release","volume":"11","author":"Peppas","year":"1993","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.lfs.2019.02.029_bb0410","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.clae.2007.09.002","article-title":"Polymeric hydrogels for novel contact lens-based ophthalmic drug delivery systems: a review","volume":"31","author":"Xinming","year":"2008","journal-title":"Cont. Lens Anterior Eye"},{"key":"10.1016\/j.lfs.2019.02.029_bb0415","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.exer.2018.11.017","article-title":"Thermosensitive chitosan-gelatin-based hydrogel containing curcumin-loaded nanoparticles and latanoprost as a dual-drug delivery system for glaucoma treatment","volume":"179","author":"Cheng","year":"2019","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.lfs.2019.02.029_bb0420","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1021\/acs.molpharmaceut.7b00615","article-title":"Self-assembling elastin-like hydrogels for timolol delivery: development of an ophthalmic formulation against glaucoma","volume":"14","author":"Fern\u00e1ndez-Colino","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.lfs.2019.02.029_bb0425","first-page":"155","article-title":"Cascade\u2032-and\u2032 nonskid-chain-like\u2032 syntheses of molecular cavity topologies","volume":"9","author":"Buhleier","year":"1978","journal-title":"Chemi. scher. Informations. Dienst."},{"key":"10.1016\/j.lfs.2019.02.029_bb0430","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.addr.2005.09.011","article-title":"Characterization of dendrimers","volume":"57","author":"Caminade","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.lfs.2019.02.029_bb0435","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ejmech.2009.10.017","article-title":"Designing dendrimers for ocular drug delivery","volume":"45","author":"Spataro","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.lfs.2019.02.029_bb0440","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejps.2009.07.008","article-title":"Dendrimers: emerging polymers for drug-delivery systems","volume":"38","author":"Nanjwade","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.lfs.2019.02.029_bb0445","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2004.09.015","article-title":"Poly (amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide","volume":"102","author":"Vandamme","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2019.02.029_bb0450","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.drudis.2007.10.021","article-title":"Nanotechnology in ocular drug delivery","volume":"13","author":"Sahoo","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.lfs.2019.02.029_bb0455","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/jphp.12587","article-title":"Dexamethasone - PAMAM dendrimer conjugates for retinal delivery: preparation, characterization and in vivo evaluation","volume":"68","author":"Yavuz","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.lfs.2019.02.029_bb0460","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1021\/acsbiomaterials.7b00319","article-title":"Fast dissolving dendrimernanofiber mats as alternative to eye drops for more efficient antiglaucoma drug delivery","volume":"3","author":"Lancina","year":"2017","journal-title":"ACS Biomater Sci. Eng."},{"key":"10.1016\/j.lfs.2019.02.029_bb0465","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3129\/i10-090","article-title":"Nanotechnology in ophthalmology","volume":"45","author":"Zarbin","year":"2010","journal-title":"Can. J. Ophthalmol."},{"key":"10.1016\/j.lfs.2019.02.029_bb0470","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2008.12.018","article-title":"Polymeric nanoparticulate system: a potential approach for ocular drug delivery","volume":"136","author":"Nagarwal","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2019.02.029_bb0475","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3109\/10611860903450023","article-title":"Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation","volume":"18","author":"Wadhwa","year":"2010","journal-title":"J. Drug Target."},{"key":"10.1016\/j.lfs.2019.02.029_bb0480","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.carbpol.2009.10.038","article-title":"Novel carboxymethyl chitin nanoparticles for cancer drug delivery applications","volume":"79","author":"Dev","year":"2010","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.lfs.2019.02.029_bb0485","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.pmatsci.2010.03.001","article-title":"Novel carboxymethyl derivatives of chitin and chitosan materials and their biomedical applications","volume":"55","author":"Jayakumar","year":"2010","journal-title":"Prog. Mater. Sci."},{"key":"10.1016\/j.lfs.2019.02.029_bb0490","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.2147\/IJN.S162306","article-title":"Montmorillonite\/chitosan nanoparticles as a novel controlled-release topical ophthalmic delivery system for the treatment of glaucoma","volume":"13","author":"Li","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.lfs.2019.02.029_bb0495","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1208\/s12249-016-0669-x","article-title":"Development of timolol-loaded galactosylated chitosan nanoparticles and evaluation of their potential for ocular drug delivery","volume":"18","author":"Zhao","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.lfs.2019.02.029_bb0500","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.colsurfb.2014.07.004","article-title":"Dorzolamide-loaded PLGA\/vitamin E TPGS nanoparticles for glaucoma therapy: pharmacoscintigraphy study and evaluation of extended ocular hypotensive effect in rabbits","volume":"122","author":"Warsi","year":"2014","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.lfs.2019.02.029_bb0505","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1208\/s12249-017-0710-8","article-title":"PLGA nanoparticles as subconjunctival injection for management of glaucoma","volume":"18","author":"Salama","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.lfs.2019.02.029_bb0510","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ijbiomac.2018.04.122","article-title":"Chitosan coated PLGA nanoparticles amplify the ocular hypotensive effect of forskolin: statistical design, characterization and in vivo studies","volume":"116","author":"Khan","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.lfs.2019.02.029_bb0515","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijpharm.2018.04.059","article-title":"Exploring gelatin nanoparticles as novel nanocarriers for timolol maleate: augmented in-vivo efficacy and safe histological profile","volume":"545","author":"Shokry","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.lfs.2019.02.029_bb0520","doi-asserted-by":"crossref","first-page":"7008","DOI":"10.1039\/C7TB01217A","article-title":"Gelatin-functionalized mesoporous silica nanoparticles with sustained release properties for intracameral pharmacotherapy of glaucoma","volume":"5","author":"Liao","year":"2017","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.lfs.2019.02.029_bb0525","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3109\/02652048.2010.539304","article-title":"A potential new therapeutic system for glaucoma: solid lipid nanoparticles containing methazolamide","volume":"28","author":"Li","year":"2011","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.lfs.2019.02.029_bb0530","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijpharm.2014.11.032","article-title":"Cationic solid lipid nanoparticles enhance ocular hypotensive effect of melatonin in rabbit","volume":"478","author":"Leonardi","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.lfs.2019.02.029_bb0535","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.drudis.2010.12.004","article-title":"Drug delivery to the posterior segment of the eye","volume":"16","author":"Thrimawithana","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.lfs.2019.02.029_bb0540","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11095-008-9756-3","article-title":"Intrascleral drug delivery to the eye using hollow microneedles","volume":"26","author":"Jiang","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.lfs.2019.02.029_bb0545","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1167\/iovs.07-0066","article-title":"Coated microneedles for drug delivery to the eye","volume":"48","author":"Jiang","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.lfs.2019.02.029_bb0550","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.colsurfb.2017.08.037","article-title":"Octa-arginine modified lipid emulsions as a potential ocular delivery system for disulfiram: a study of the corneal permeation, transcorneal mechanism and anti-cataract effect","volume":"160","author":"Liu","year":"2017","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.lfs.2019.02.029_bb0555","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/02713680802023104","article-title":"Formulation and evaluation of ciprofloxacin hydrochloride soluble ocular drug insert","volume":"33","author":"Mundada","year":"2008","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.lfs.2019.02.029_bb0560","first-page":"320","article-title":"A summary of recent advances in ocular inserts and implants","volume":"9","author":"Jervis","year":"2017","journal-title":"J. Bioequiv. Availab"},{"key":"10.1016\/j.lfs.2019.02.029_bb0565","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4103\/0110-5558.72419","article-title":"Ocular inserts\u2014advancement in therapy of eye diseases","volume":"1","author":"Kumari","year":"2010","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"10.1016\/j.lfs.2019.02.029_bb0570","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jddst.2016.01.008","article-title":"Ocular inserts based on chitosan and brimonidine tartrate: development, characterization and biocompatibility","volume":"32 (","author":"De Souza","year":"2016","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.lfs.2019.02.029_bb0575","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095461","article-title":"Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluation","volume":"9","author":"Franca","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2019.02.029_bb0580","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.ophtha.2016.04.026","article-title":"Six-month intraocular pressure reduction with a topical bimatoprost ocular insert: results of a phase II randomized controlled study","volume":"123","author":"Brandt","year":"2016","journal-title":"Ophthalmology."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320519301195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320519301195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:23:38Z","timestamp":1758399818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320519301195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":116,"alternative-id":["S0024320519301195"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2019.02.029","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glaucoma: Current treatment and impact of advanced drug delivery systems","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2019.02.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}